I kappa B-epsilon Antibody (F-9): sc-365899
- IκB-ε Antibody (F-9) is a mouse monoclonal IgG2a κ provided at 200 µg/ml
- raised against amino acids 1-365 of IκB-ε of mouse origin
- recommended for detection of IκB-ε of mouse, rat and human origin by WB, IP, IF and ELISA
- m-IgGκ BP-HRP is the preferred secondary detection reagent for IκB-ε Antibody (F-9) for WB applications. This reagent is now offered in a bundle with IκB-ε Antibody (F-9) (see ordering information below). For additional m-IgGκ BP conjugates see our complete list of Mouse IgG Binding Proteins.
QUICK LINKS
IκB-ε Antibody (F-9) is a mouse monoclonal IgG2a antibody that detects IκB-ε in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). IκB-ε plays a crucial role in regulating the NF-kB signaling pathway, which is essential for controlling immune responses, cell proliferation, and survival. IκB-ε is primarily located in the cytoplasm, where IκB-ε binds to the RelA and c-Rel subunits of NF-kB, preventing their translocation to the nucleus and thereby inhibiting the expression of target genes involved in inflammation and immune responses. Proper functioning of IκB-ε is vital, as dysregulation can lead to various diseases, including cancer and autoimmune disorders. Additionally, IκB-ε undergoes post-translational modifications, such as phosphorylation, which can influence stability and interaction with NF-kB complexes, further emphasizing importance in cellular signaling and homeostasis. Anti-IκB-ε antibody (F-9) is an invaluable tool for researchers studying the intricate mechanisms of NF-kB regulation and its implications in health and disease.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
I kappa B-epsilon Antibody (F-9) References:
- IkappaBepsilon-deficient mice: reduction of one T cell precursor subspecies and enhanced Ig isotype switching and cytokine synthesis. | Mémet, S., et al. 1999. J Immunol. 163: 5994-6005. PMID: 10570287
- A functional role of I kappa B-epsilon in endothelial cell activation. | Spiecker, M., et al. 2000. J Immunol. 164: 3316-22. PMID: 10706725
- Chlamydia pneumoniae activates IKK/I kappa B-mediated signaling, which is inhibited by 4-HNE and following primary exposure. | Donath, B., et al. 2002. Atherosclerosis. 165: 79-88. PMID: 12208473
- Inactivating I kappa B epsilon mutations in Hodgkin/Reed-Sternberg cells. | Emmerich, F., et al. 2003. J Pathol. 201: 413-20. PMID: 14595753
- Combined deficiency in IkappaBalpha and IkappaBepsilon reveals a critical window of NF-kappaB activity in natural killer cell differentiation. | Samson, SI., et al. 2004. Blood. 103: 4573-80. PMID: 14764534
- Reductions in I kappa B epsilon and changes in NF-kappa B activity during B lymphocyte differentiation. | Doerre, S., et al. 2005. J Immunol. 174: 983-91. PMID: 15634922
- NFKBIE mutations are selected by the tumor microenvironment and contribute to immune escape in chronic lymphocytic leukemia. | Bonato, A., et al. 2024. Leukemia. 38: 1511-1521. PMID: 38486128
- IκBε deficiency accelerates disease development in chronic lymphocytic leukemia. | Bordini, J., et al. 2024. Leukemia. 38: 1287-1298. PMID: 38575671
- I kappa B epsilon, a novel member of the I kappa B family, controls RelA and cRel NF-kappa B activity. | Whiteside, ST., et al. 1997. EMBO J. 16: 1413-26. PMID: 9135156
- Control of NF-kappa B activity by the I kappa B beta inhibitor. | Weil, R., et al. 1997. Immunobiology. 198: 14-23. PMID: 9442374
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
IκB-ε Antibody (F-9) | sc-365899 | 200 µg/ml | $322.00 | |||
IκB-ε Antibody (F-9): m-IgGκ BP-HRP Bundle | sc-552368 | 200 µg Ab; 40 µg BP | $361.00 |